Investigational drug · Phase 3
NX-5948
Also called: bexobrutideg
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "NX-5948"
First trial start
2025
Oct 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NX-5948", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "NX-5948" as an intervention, largest first.
- Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLLPivotal-lookingRecruiting
Nurix Therapeutics, Inc.Industry
NCT07516093 · 620 participants (planned) · Start Aug 3, 2026 · Primary completion Oct 2029
Drug: NX-5948; Pirtobrutinib · For: B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Macon, Georgia; Fort Wayne, Indiana; Indianapolis, Indiana · 6 sites in all
Nurix Therapeutics, Inc.Industry
NCT05131022 · 572 participants (planned) · Start Apr 13, 2022 · Primary completion Jan 2027
Drug: NX-5948 · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Diffuse Large B Cell Lymphoma (DLBCL) and 6 more
Sites: Duarte, California; San Francisco, California; Denver, Colorado · 62 sites in all
Nurix Therapeutics, Inc.Industry
NCT06717269 · 223 participants · Start Nov 30, 2024 · Primary completion May 1, 2026
Drug: NX-5948; Esomeprazole and 7 more · For: Healthy Volunteer
Sites: Phoenix, Arizona; Lincoln, Nebraska
Nurix Therapeutics, Inc.Industry
NCT07520006 · 150 participants (planned) · Start Sep 30, 2026 · Primary completion May 2033
Drug: NX-5948; venetoclax and 2 more · For: B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Sites: Irvine, California; Aurora, Colorado; Coral Gables, Florida · 10 sites in all
Nurix Therapeutics, Inc.Industry
NCT07221500 · 100 participants (planned) · Start Oct 15, 2025 · Primary completion Jan 2028
Drug: NX-5948 · For: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL)
Sites: Phoenix, Arizona; Duarte, California; Irvine, California · 47 sites in all
Nurix Therapeutics, Inc.Industry
NCT06593457 · 32 participants · Start Aug 20, 2024 · Primary completion Oct 29, 2024
Drug: IP; Matching Placebo · For: Healthy Volunteers
Sites: Lincoln, Nebraska
- Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948Completed
Nurix Therapeutics, Inc.Industry
NCT06691828 · 8 participants · Start Nov 1, 2024 · Primary completion Nov 28, 2024
Drug: NX-5948 · For: Healthy Volunteer
Sites: Lincoln, Nebraska
Newest research
PubMed records naming it or its code names, newest first.
- PROTAC degraders for lymphoid malignancies - current status and future directions.
Wolska-Washer A, Robak T · Expert Opin Emerg Drugs 2026
- Emerging drug profile: bexobrutideg.
Huynh T, Rodriguez-Rodriguez S, Danilov AV · Leuk Lymphoma 2026
- Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting hemostasis.
May CJ, Trory JS, Webb CE, et al. · Blood Adv 2026
- Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors.
Sievers Q, Lu H, Cool A, et al. · Cancer Discov 2026
- Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting.
Sharma P, Jiang H, Liu D · J Hematol Oncol 2026
- Bruton Tyrosine Kinase Degraders: Current Concepts.
Sabakhtarishvili G, Alshebli M, Bajwa O, et al. · Am J Clin Oncol 2025
Also in development for B-cell Lymphoma
- Zugocabtagene geleucelCTX112Phase 23 trials
CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy
- TQB3702Phase 22 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · B-cell Lymphoma, Systemic Lupus Erythematosus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.